Hutchmed

Eli Lilly partner Hutchmed scraps China stomach cancer filing as approval seems unlikely
Fierce Pharma
Fri, 08/30/24 - 11:40 am
Hutchmed
Eli Lilly
Fruzaqla
China
stomach cancer
Hutchmed eyes Chinese approval for autoimmune disorder drug after phase 3 success
Fierce Biotech
Mon, 08/21/23 - 10:36 am
Hutchmed
sovleplenib
China
clinical trials
autoimmune disease
FDA Clears Taiho’s Lonsurf in Metastatic Colorectal Cancer Ahead of Takeda, Hutchmed
BioSpace
Thu, 08/3/23 - 10:23 am
Taiho Oncology
Lonsurf
colorectal cancer
FDA
Takeda
Hutchmed
FDA grants priority review for Takeda and HUTCHMED’s fruquintinib NDA
Pharmaceutical Technology
Fri, 05/26/23 - 11:31 am
Takeda
Hutchmed
FDA
fruquintinib
colorectal cancer
Takeda Oncology Invests in Talent, Pipeline Growth Despite Turbulent Market
BioSpace
Mon, 03/20/23 - 09:55 am
Takeda Oncology
innovation
Hutchmed
Takeda focuses on ‘diverse’ pipeline prospects on heels of two acquisitions
Endpoints
Mon, 02/6/23 - 10:55 am
Takeda
Nimbus Therapeutics
Hutchmed
colorectal cancer
psoriasis
fruquintinib
The world's twelfth VEGF drug will be sold by Takeda
EP Vantage
Mon, 01/23/23 - 10:43 am
Takeda
Hutchmed
VEGF
fruquintinib
Hutchmed reports positive data from gastric cancer therapy trial
Clinical Trials Arena
Mon, 11/14/22 - 07:09 pm
Hutchmed
fruquintinib
clinical trials
gastric cancer
AstraZeneca pushes forward with Tagrisso combos, touting PhII data with Hutchmed drug
Endpoints
Mon, 08/8/22 - 09:54 am
AstraZeneca
Hutchmed
clinical trials
Tagrisso
savolitinib
lung cancer
US Bridging Study Not Enough as FDA Denies Hutchmed's Pancreatic Cancer Drug
BioSpace
Mon, 05/2/22 - 06:32 pm
FDA
Hutchmed
pancreatic cancer
surufatinib